Pahlman and colleagues (Pietras et al, 2008) demonstrated that expression of HIF2α, specifically, denotes neuroblastoma and breast cancer cells with a more immature phenotype and the presence of HIF2α-positive cells correlates to poor patient outcome. The gene discussed is EPAS1; the disease is neuroblastoma.